Please login to the form below

Not currently logged in
Email:
Password:

CSU

This page shows the latest CSU news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals positive efficacy data for Xolair follow-up

Novartis reveals positive efficacy data for Xolair follow-up

The new treatment is being studied in chronic spontaneous urticaria (CSU), one of Xolair’s  approved indications. ... This mechanistic study further supports those findings as we look to reimagine care to bring better treatment options for patients

Latest news

  • 90TEN and ICG win market research award at Communiqué 2015 90TEN and ICG win market research award at Communiqué 2015

    Their'Wheals of Despair'campaign, created for Novartis UK, focused on chronic spontaneous urticaria (CSU) - a condition that was until recently a mystery to many doctors and almost completely unknown to ... Characterised by excruciating wheals, swelling

  • NICE set to back Novartis' Xolair for skin condition CSU NICE set to back Novartis' Xolair for skin condition CSU

    NICE is poised to recommend Novartis' Xolair as an add-on treatment option for severe chronic spontaneous urticaria (CSU) in adults after the company was able to provide more information on ... CSU is often characterised by itching and hives, or wheals,

  • Novartis' dermatology plans advance with Xolair approval Novartis' dermatology plans advance with Xolair approval

    Xolair for CSU is one of two drugs nearing the market in the dermatology category that Novartis has high hopes for. ... having the CSU market to itself for up to 10 years, as there are no competitors on the horizon at the moment.

  • CHMP backs Xolair for severe hives CHMP backs Xolair for severe hives

    Around half of all CSU patients do not respond even to high-dose antihistamine therapy. ... CSU leaves patients in constant fear of when the next attack is going to occur,” he added.

  • Novartis' omalizumab effective in chronic skin disease Novartis' omalizumab effective in chronic skin disease

    The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the ... Novartis filed for approval of omalizumab a few weeks ago as a

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Double Communiqué award win for 90TEN

    to 500, 000 Britons and having a major impact on quality of life, chronic spon taneous urticaria (CSU) – a type of severe hives – was, until recently, a mystery to many doctors ... compelling patient resource and a hard-hitting campaign full of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics